Matthew Weinstock

Acalabrutinib, venetoclax, and obinutuzumab as frontline treatment for chronic lymphocytic leukaemia: a single-arm, open-label, phase 2 study

Matthew S. Davids, Benjamin L. Lampson, Svitlana Tyekucheva et al. · The Lancet Oncology · 2021 · 102 citations

Medicine, Hematology, Pharmacology +11

Development of extramedullary myeloma in the era of novel agents: no evidence of increased risk with lenalidomide–bortezomib combinations

Cindy Varga, Wanling Xie, Jacob P. Laubach et al. · British Journal of Haematology · 2015 · 82 citations · Full text

Medicine, Hematology, Pharmacotherapy +17

Safety and clinical activity of vascular endothelial growth factor receptor (VEGFR)–tyrosine kinase inhibitors after programmed cell death 1 inhibitor treatment in patients with metastatic clear cell renal cell carcinoma

Rosa Nadal, A. Amin, Daniel M. Geynisman et al. · Annals of Oncology · 2016 · 76 citations · Full text

Medicine, Oncology, Pharmacology +17

Hypomethylating agent alters the immune microenvironment in acute myeloid leukaemia (AML) and enhances the immunogenicity of a dendritic cell/AML vaccine

Myrna Nahas, Dina Stroopinsky, Jacalyn Rosenblatt et al. · British Journal of Haematology · 2019 · 72 citations · Full text

Medicine, Immunology, Oncology +17

Antibody optimization enabled by artificial intelligence predictions of binding affinity and naturalness

Sharrol Bachas, Goran Rakočević, David A. Spencer et al. · bioRxiv (Cold Spring Harbor Laboratory) · 2022 · 67 citations · Full text

Pharmacy, Bioinformatics, Biotechnology +17